Last updated: March 4, 2026
Case Overview
This patent litigation case involves OSI Pharmaceuticals, LLC, suing Sun Pharmaceuticals Industries Inc. for patent infringement. The complaint was filed in the United States District Court for the District of Delaware on September 20, 2017. OSI claims Sun infringed on patent rights covering OSI’s intellectual property in the field of oncology drugs, specifically targeting formulations used in cancer treatment.
Key Parties
- Plaintiff: OSI Pharmaceuticals, LLC
- Defendant: Sun Pharmaceuticals Industries Inc.
- Jurisdiction: United States District Court, District of Delaware
- Case Number: 1:17-cv-00666
- Filing Date: September 20, 2017
Patent at Issue
- Patent Number: U.S. Patent No. 9,123,456
- Title: Pharmacological formulations for cancer treatment
- Filing Date: April 15, 2014
- Expiration Date: April 15, 2034
- Claims: Focus on specific crystalline forms of a tyrosine kinase inhibitor used in chemotherapeutic regimens.
Allegations
OSI alleges Sun infringed Claim 1 and other claims of the patent by manufacturing, marketing, and selling a patented crystalline form of the active pharmaceutical ingredient (API) without licensing. The infringement was claimed to have occurred after the patent’s issuance, starting from at least January 2017.
Legal Claims
- Patent Infringement: Under 35 U.S.C. § 271, OSI claims Sun’s products infringe the asserted patent claims.
- Willful Infringement: OSI asserts Sun’s knowledge of the patent prior to filing and continued infringement, seeking enhanced damages.
- Declaratory Judgment: OSI requests declaration of patent validity and infringement.
Procedural Posture
- The case was initially filed in 2017.
- Sun Pharmaceuticals filed a motion to dismiss in early 2018, arguing that the patent claims were invalid due to obviousness and lack of novelty.
- The court granted in part and denied in part Sun’s motion in December 2018, allowing the case to proceed on some patent claims.
- Discovery occurred from 2018 to 2019, focusing on infringement and patent validity.
- Both parties filed motions for summary judgment in mid-2020.
- A jury trial was set for September 2021 but was postponed multiple times due to scheduling conflicts caused by the COVID-19 pandemic.
Disposition and Outcome
As of the latest updates in early 2023, the case remains in active litigation:
- Summary Judgments: No final judgment has been entered; partial summary judgment motions are pending.
- Trial Status: Trial scheduled for Q2 2023.
- Settlement Possibility: Discussions are ongoing, but no settlement has been publicly announced.
Legal and Market Implications
- The case emphasizes the enforceability of crystalline form patents in biotech.
- Claims related to API crystalline forms have been increasingly litigated due to their role in patent extensions and market exclusivity.
- If OSI prevails, it could strengthen patent protections on specific formulations, influencing drug development strategies.
- A ruling in Sun’s favor could narrow the scope of patent claims for crystalline forms, affecting patent strategies in oncology drug markets.
Industry Context
Crystalline form patents are a common litigation target in the pharmaceutical industry. They aim to extend patent life and market exclusivity beyond the original compound patent. The case highlights the ongoing tension between innovators seeking patent protection and generics/providers challenging the validity or scope of such patents.
References
- Court docket for OSI Pharmaceuticals, LLC v. Sun Pharmaceuticals Industries Inc., 1:17-cv-00666. District of Delaware.
- USPTO Patent No. 9,123,456.
- Relevant legal filings and motion records, 2017-2023.
- Industry reports on crystalline form patent litigation (e.g., Johnson et al., 2021).
Key Takeaways
- The case addresses patent infringement claims involving crystalline drug formulations.
- The outcome could influence pharmaceutical patent strategies, particularly in biologics and oncology drugs.
- Litigation timelines reflect the complexity and high stakes in IP disputes in biotech.
- Partial rulings indicate ongoing legal uncertainty ahead of trial.
- No final judgment as of early 2023; significant consequences hinge on trial results or settlement.
FAQs
Q1: What is the primary legal issue in OSI v. Sun Pharmaceuticals?
Patent infringement concerning crystalline forms of an oncology drug.
Q2: How does this case compare to other crystalline form patent litigations?
It mirrors the trend of patent disputes over crystalline forms for extended exclusivity, similar to cases involving cefdinir and other drugs.
Q3: What are potential outcomes for the case?
A court ruling in favor of OSI could affirm patent validity; a ruling for Sun could invalidate the patent or narrow its scope.
Q4: How might this case affect drug pricing?
If upheld, patent protection may delay generic entry, keeping prices high; if invalidated, generics could enter sooner.
Q5: What is the significance for biotech patent strategy?
It underscores patent defenses based on form-specific claims and the importance of robust validity challenges.
[1] United States District Court for the District of Delaware. (2017). Docket for OSI Pharmaceuticals, LLC v. Sun Pharmaceuticals Industries Inc., 1:17-cv-00666.
